ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-emitting isotope (Pb212) and tumor-specific targets to create highly targeted therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. Learn more: www.artbiotx.com
Location: Switzerland, Basel-City, Basel
Total raised: $90M
Investors 1
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.12.2023 | - | $90M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 28.02.2024 | ARTBIO Collaborates with AlphaGen Therapeutics, and Enters i... | - | fprimecapi... |
| 20.02.2024 | AlphaGen Therapeutics and ARTBIO Announce Exclusive Strategi... | - | fprimecapi... |
| 07.12.2023 | ARTBIO raises $90M as radiopharma field finds its footing | - | fprimecapi... |